Olaparib approved in Scotland as new ovarian cancer treatment
Clinical trial with key contributions from Cancer Research UK Edinburgh Centre clinicians leads to approval of cancer drug olaparib as new ovarian cancer treatment in Scotland: December 2019
More than 350 women die from ovarian cancer in Scotland each year. Professor Charlie Gourley from the CRUK Edinburgh Centre is the UK lead of the pivotal SOLO-1 clinical trial that helped to approve olaparib as maintenance treatment for patients with advanced ovarian cancer and brought new hope to ovarian cancer patients.
Read the story on BBC website Read the story on STV website
- Professor Charlie Gourley Group website: https://www.ed.ac.uk/cancer-centre/research/gourley-group
- Learn more about ovarian cancer: https://www.cancerresearchuk.org/about-cancer/ovarian-cancer